Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients

Sponsor
Vastra Gotaland Region
Study ID
NCT03440892
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • methotrexate — DRUG
    folate antagonist
  • sulfasalazine — DRUG
    Immunomodulatory
  • abatacept — DRUG
    Targeting CTLA-4 (fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4)
  • tocilizumab — DRUG
    IL-6 receptor antagonist
  • tofacitinib/baricitinib — DRUG
    JAK inhibitor

Study Details

To validate the utility of survivin as a biomarker of pharmacological response to therapeutic intervention in rheumatoid arthritis patients.

Key Dates

Start date
Nov 1, 2017
Status verified
May 2022
Primary completion
Jan 31, 2025
Completion
Jan 31, 2025

Study Design

Enrollment
2,500 participants (estimated)

Arms

  • Arm: 1

Primary Outcome Measure

Survivin status [ Time Frame: 6 months ]

Central Contacts

Related Studies